Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

Abstract

Brodalumab significantly improved response rates among patients with psoriatic arthritis. Larger studies of longer duration are necessary to assess adverse events. (Funded by Amgen; ClinicalTrials.gov number, NCT01516957 .).